JB Chemicals and Pharmaceuticals Ltd is recalling approximately 23,376 bottles of Cetirizine Hydrochloride Tablets USP (10 mg) because the tablets or capsules were imprinted with the wrong identification codes. This recall affects both 100-count and 500-count bottles manufactured in India and distributed across the United States. While the medication itself is the correct strength and generic type, the incorrect marking could lead to identification errors for patients and healthcare providers.
The tablets contain the correct medication, but the incorrect identification imprint can lead to confusion, potentially causing patients to take the wrong medication or doubt their treatment regimen.
You have 2 options:
Manufactured by Unique Pharmaceuticals Labs (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.)
Manufactured by Unique Pharmaceuticals Labs (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.)
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.